GPIIb/IIIa antagonists: the good, the bad and the not too ugly

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1616, 2007-01, pp. : 19-19

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Update on GPIIb/IIIa antagonists

By Hanson Julien de Leval Xavier Kolh Philippe Supuran Claudiu Pirotte Bernard Dogné Jean-Michel

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 8, 2003-08 ,pp. : 1173-1188

Informa Healthcare

Access to resources Recommend Favorite

Bivalirudin benefit independent of GPIIb-IIIa antagonists

Inpharma, Vol. 1, Iss. 1632, 2008-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

GPIIb-IIIa antagonists in ACS and renal impairment

Inpharma, Vol. 1, Iss. 1385, 2003-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

GPIIb-IIIa antagonists: upstream vs deferred use in acute coronary syndromes

Inpharma, Vol. 1, Iss. 1576, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

GPIIb-IIIa antagonists cost effective in acute coronary syndromes

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 499, 2006-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite